scholarly journals A One-Year Economic Evaluation of Six Alternative Strategies for the Management of Uninvestigated Upper Gastrointestinal Symptoms in Canadian Primary Care

2010 ◽  
Vol 24 (8) ◽  
pp. 489-498 ◽  
Author(s):  
Alan N Barkun ◽  
Ralph Crott ◽  
Carlo A Fallone ◽  
Wendy A Kennedy ◽  
Jean Lachaine ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Gastrointestinal Symptoms ◽  
Cost Effective ◽  
Upper Gastrointestinal Symptoms ◽  
Management Approaches ◽  
The Cost ◽  
Relevant Range ◽  
Upper Gastrointestinal

BACKGROUND: The cost-effectiveness of initial strategies in managing Canadian patients with uninvestigated upper gastrointestinal symptoms remains controversial.OBJECTIVE: To assess the cost-effectiveness of six management approaches to uninvestigated upper gastrointestinal symptoms in the Canadian setting.METHODS: The present study analyzed data from four randomized trials assessing homogeneous and complementary populations of Canadian patients with uninvestigated upper gastrointestinal symptoms with comparable outcomes. Symptom-free months, quality-adjusted life-years (QALYs) and direct costs in Canadian dollars of two management approaches based on the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool, and four additional strategies (two empirical antisecretory agents, and two prompt endoscopy) were examined and compared. Prevalence data, probabilities, utilities and costs were included in a Markov model, while sensitivity analysis used Monte Carlo simulations. Incremental cost-effectiveness ratios and cost-effectiveness acceptability curves were determined.RESULTS: Empirical omeprazole cost $226 per QALY ($49 per symptom-free month) per patient. CanDys omeprazole and endoscopy approaches were more effective than empirical omeprazole, but more costly. Alternatives using H2-receptor antagonists were less effective than those using a proton pump inhibitor. No significant differences were found for most incremental cost-effectiveness ratios. As willingness to pay (WTP) thresholds rose from $226 to $24,000 per QALY, empirical antisecretory approaches were less likely to be the most cost-effective choice, with CanDys omeprazole progressively becoming a more likely option. For WTP values ranging from $24,000 to $70,000 per QALY, the most clinically relevant range, CanDys omeprazole was the most cost-effective strategy (32% to 46% of the time), with prompt endoscopy-proton pump inhibitor favoured at higher WTP values.CONCLUSIONS: Although no strategy was the indisputable cost-effective option, CanDys omeprazole may be the strategy of choice over a clinically relevant range of WTP assumptions in the initial management of Canadian patients with uninvestigated dyspepsia.

The Cost-Effectiveness of IV Versus PO Proton Pump Inhibitor (PPI) Therapy in the Management of High-Risk Ulcer Hemorrhage

2005 ◽  
Vol 61 (5) ◽  
pp. AB156
Author(s):  
Brennan Spiegel ◽  
Brian Lim ◽  
Gareth S. Dulai ◽  
Neel Mann ◽  
Fasiha Kanwal ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
High Risk ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
The Cost ◽  
Ulcer Hemorrhage

scholarly journals Validation of a Short Questionnaire in English and French for Use in Patients with Persistent Upper Gastrointestinal Symptoms Despite Proton Pump Inhibitor Therapy: The Pass (Proton Pump Inhibitor Acid Suppression Symptom) Test

2005 ◽  
Vol 19 (6) ◽  
pp. 350-358 ◽  
Author(s):  
David Armstrong ◽  
Sander JO Veldhuyzen van Zanten ◽  
Sharon A Chung ◽  
Colin M Shapiro ◽  
Sukhjeet Dhillon ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Reflux Disease ◽  
Content Validity ◽  
Gastrointestinal Symptoms ◽  
Acid Suppression ◽  
Persistent Symptoms ◽  
French Speaking ◽  
Upper Gastrointestinal Symptoms ◽  
Test Retest Reliability

BACKGROUND: The management of persistent symptoms during acid suppression therapy in patients with gastroesophageal reflux disease or dyspepsia might be improved if patient-physician communication regarding the presence and character of these persistent symptoms were facilitated.AIM: To validate a short, simple questionnaire (the Proton pump inhibitor [PPI] Acid Suppression Symptom [PASS] test), in English and French, to identify patients with persistent acid-related symptoms during PPI therapy and document their response to a change in therapy.METHODS: Patients with persistent acid-related symptoms on PPI therapy were interviewed to produce a draft, five-item questionnaire; content validity was evaluated by focus groups comprising English- and French-speaking patients. Psychometric validity was subsequently evaluated in a multicentre, family practice-based study of English- and French-speaking patients with persistent acid-related upper gastrointestinal symptoms despite PPI therapy. The PASS test, Global Overall Symptom scale, Gastrointestinal Symptom Rating Scale (GSRS), Quality of Life in Reflux and Dyspepsia questionnaire and Reflux Disease Questionnaire were completed at baseline and repeated after one week while patients continued their original PPI therapy. All patients then received esomeprazole 40 mg once daily for four weeks, after which all questionnaires and an evaluation of overall treatment effect were completed.RESULTS: Content validity was established in 20 English- and 16 French-speaking patients. Psychometric validation in 158 English- and 113 French-speaking patients revealed good-to-excellent test-retest reliability coefficients: 0.76 for English; 0.68 for French. For construct validity, the PASS test showed moderate-to-high correlation with the GSRS scale (0.51 for English; 0.43 for French). After four weeks of therapy, the PASS test score fell to zero in 30% of English- and 33% of French-speaking patients, while the Global Overall Symptom score fell to one (no symptoms) in 32% of patients (English- and French-speaking); the PASS test demonstrated good responsiveness in comparison with the GSRS, Reflux Disease Questionnaire and Quality of Life in Reflux and Dyspepsia questionnaire.CONCLUSION: The five-item PASS test is a valid tool for the evaluation of persistent acid-related symptoms in patients receiving PPI therapy. It demonstrates good content validity, test-retest reliability, responsiveness and construct validity in both English and French forms. The PASS test is a simple, clinically applicable tool for the identification of patients with persistent acid-related symptoms during therapy and the assessment of their responses to a change in therapy.

scholarly journals Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Xueshan Sun ◽  
Xuemei Zhen ◽  
Xiaoqian Hu ◽  
Yuanyuan Li ◽  
ShuYan Gu ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Adverse Events ◽  
Proton Pump ◽  
Treatment Strategies ◽  
Cost Effective ◽  
Cost Utility ◽  
Sensitivity Analyses ◽  
Medical Database ◽  
Utility Analysis ◽  
The Cost

Abstract Background To estimate the cost -utility of imrecoxib compared with diclofenac, as well as the addition of a proton pump inhibitor to both two treatment strategies, for patients with osteoarthritis, from a Chinese healthcare perspective. Methods A Markov model was built. Costs of managing osteoarthritis and initial adverse events were collected from a Medical Database which collected information from 170 hospitals. Other parameters were obtained from the literature. Subgroup analyses were conducted for people at high risk of gastrointestinal or cardiovascular adverse events. Deterministic and probabilistic sensitivity analyses were performed. Results Imrecoxib was highly cost-effective than diclofenac (the ICER was $401.58 and $492.77 in patients at low and high gastrointestinal and cardiovascular risk, respectively). The addition of a proton pump inhibitor was more cost -effective compared with single drug for both treatment strategies. Findings remained robust to sensitivity analyses. 59.04% and 57.16% probability for the co-prescription of imrecoxib and a proton pump inhibitor to be the most cost-effective strategy in all patients considered using the cost-effectiveness threshold of $30,000. Conclusions The addition of a proton pump inhibitor to both imrecoxib and diclofenac was advised. Imrecoxib provides a valuable option for patients with osteoarthritis. Uncertainties existed in the model, and the suggestions can be adopted with caution.

Sign in / Sign up

Export Citation Format

Share Document